A mineralocorticoid receptor antagonist is a diuretic drug which antagonizes (or blocks) the action of aldosterone at mineralocorticoid receptors. This is the primary class of drug used to treat primary aldosteronism. Spironolactone and Eplerenone are MRAs.
Mineralocorticoid receptor antagonist (MRA)
Index
- ACE inhibitor
- ACTH
- Adenoma
- Adrenal gland
- Adrenal Venous Sampling (AVS)
- Adrenalectomy
- Adrenocortical carcinoma
- Aldosterone
- Aldosterone synthase inhibitors
- Aldosterone-producing adenoma
- Aldosteronoma
- Amiloride
- Angiotensin receptor blocker (ARB)
- Atrial fibrilation
- Calcium channel blocker
- Cardiologist
- Cardiovascular
- Conn’s Syndrome
- Cortisol
- Cosyntropin
- CT scan
- Cushing’s Syndrome
- DASH diet
- Diabetes mellitus
- Diuretic
- Echocardiogram
- Ectopic tumor
- Edema
- Electrocardiogram (EKG or ECG)
- Endocrinologist
- Hypernatremia
- Hypokalemia
- Incidentaloma
- Inferior Vena Cava
- Interventional radiologist
- Left Ventricular Hypertrophy (LVH)
- Mineralocorticoid receptor antagonist (MRA)
- Myocardial infarction
- Nephrologist
- Renin
- Renin-angiotensin-aldosterone system (RAAS)
- Secondary aldosteronism
- Secondary hypertension
- Sensitivity
- Sleep apnea
- Specificity
- MedTerms Medical Dictionary
- Harvard Health Medical Dictionary
- Mayo Clinic Diseases and Conditions
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young Jr, W. F. (2016). The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 101(5), 1889-1916.
- Young Jr, W. F. (2019). Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. The Journal of Internal Medicine, 285(2), 126-148.